Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+ valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in previously untreated high-risk prostate cancer.

Trial Details

NCT ID

NCT03541928

Phase

PHASE2

Sponsor

The Methodist Hospital Research Institute

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

HSV-Tk
Valacyclovir
Bicalutamide
Leuprolide Acetate
Brachytherapy, External beam radiotherapy
Radical prostatectomy

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

All patients must have biopsy proven adenocarcinoma of the prostate
Patients in should have at least one or more of the following characteristics PSA\>20, Gleason score 8-10, Primary Gleason pattern 5, \>4 cores wit…
No prior surgical, hormonal, or radiotherapy prostate treatment.
ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →